BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 30933993)

  • 1. Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.
    Mai V; Bertoletti L; Cucherat M; Jardel S; Grange C; Provencher S; Lega JC
    PLoS One; 2019; 14(4):e0214134. PubMed ID: 30933993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis.
    Marik PE; Cavallazzi R
    PLoS One; 2015; 10(11):e0143252. PubMed ID: 26587983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis.
    Rossel A; Robert-Ebadi H; Combescure C; Grosgurin O; Stirnemann J; Addeo A; Garin N; Agoritsas T; Reny JL; Marti C
    PLoS One; 2019; 14(3):e0213940. PubMed ID: 30897142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention.
    Wu C; Alotaibi GS; Alsaleh K; Linkins LA; McMurtry MS
    Thromb Res; 2015 Feb; 135(2):243-8. PubMed ID: 25488466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.
    Posch F; Königsbrügge O; Zielinski C; Pabinger I; Ay C
    Thromb Res; 2015 Sep; 136(3):582-9. PubMed ID: 26210891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis.
    Djulbegovic M; Lee AI; Chen K
    J Eval Clin Pract; 2020 Feb; 26(1):7-17. PubMed ID: 31190408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
    Prescrire Int; 2013 May; 22(138):129-33. PubMed ID: 23819181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
    Kirkilesis GI; Kakkos SK; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis.
    Mai V; Tanguay VF; Guay CA; Bertoletti L; Magnan S; Turgeon AF; Lacasse Y; Lega JC; Provencher S
    J Thromb Thrombolysis; 2020 Oct; 50(3):661-667. PubMed ID: 32052314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann HJ
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006650. PubMed ID: 18425959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Labedi N; Barba M; Terrenato I; Sperati F; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Jun; (6):CD006650. PubMed ID: 21678361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
    Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
    J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of direct oral anticoagulants in patients with chronic thromboembolic pulmonary hypertension.
    Benzidia I; Robitaille C; Abualsaud A; McDonald L; Lesenko L; Morin JF; Langleben D; Kahn SR; Hirsch A
    Thromb Res; 2023 Sep; 229():139-145. PubMed ID: 37453256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct oral anticoagulants in the treatment of acute venous thromboembolism in patients with obesity: A systematic review with meta-analysis.
    Mai V; Marceau-Ferron E; Bertoletti L; Lacasse Y; Bonnet S; Lega JC; Provencher S
    Pharmacol Res; 2021 Jan; 163():105317. PubMed ID: 33246169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using oral anticoagulants among chronic kidney disease patients to prevent recurrent venous thromboembolism: A systematic review and meta-analysis.
    Alhousani M; Malik SU; Abu-Hashyeh A; Poznanski NJ; Al-Hasan S; Roth DF; Alsharedi M; Mustafa B
    Thromb Res; 2021 Feb; 198():103-114. PubMed ID: 33310644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.